Home » Pharmaceuticals

Shares at Radius Jump as Bone Drug of Amgen Has Setback

Shares at Radius Jump as Bone Drug of Amgen Has Setback

Late Sunday Amgen revealed that safety problems emerged in its clinical testing for an osteoporosis drug known as romosozumba (Evenity). The development will at a minimum delay the path of the drug to FDA approval, if not keep it from... 
FDA Approves New Treatment for ALS

FDA Approves New Treatment for ALS

The U.S. Food and Drug Administration approved a new amyotrophic lateral sclerosis or ALS medication. The drug is Radicava and is the second drug to be given the green light by the FDA to treat ALS, also known as Lou Gehrig’s disease,... 
Valeant Pharmaceuticals Cuts Debt Following L’Oreal Deal

Valeant Pharmaceuticals Cuts Debt Following L’Oreal Deal

Valeant Pharmaceuticals International said that following its closing that was earlier than had been expected for the sale to L’Oreal of three skincare brands as well as the closing of its divestiture of a Brazil-based manufacturing... 
FDA Gives Approval to New Powerful Eczema Drug

FDA Gives Approval to New Powerful Eczema Drug

Regulators approved the first injected, powerful medicine to treat the most serious cases of eczema, a skin condition. On Tuesday, the U.S. Food and Drug Administration granted their approval of Dupixent or dupilumab for moderate to... 
Trump Tweet Sends Pharmaceutical Stocks Tumbling

Trump Tweet Sends Pharmaceutical Stocks Tumbling

On Tuesday President Donald Trump reappeared in the debate over prices of drugs and sent pharmaceutical stocks plunging again thanks to a tweet that promised medication costs would be lowered for Americans. Trump tweeted that he was... 
Shares of Kite Pharma Flying High After Reaching Study Goal

Shares of Kite Pharma Flying High After Reaching Study Goal

On Tuesday, Kite Pharma Inc. announced that CAR an experimental T-cell therapy that helps the body’s immune system to fight cancer, was very effective in the treating of aggressive non-Hodgkin’s lymphoma, as it met the main goal... 
Pharmaceuticals Shunning Push by Trump for FDA Shift

Pharmaceuticals Shunning Push by Trump for FDA Shift

President Donald Trump has vowed to roll back regulations imposed by the government by 75% or more and that has caused great anxiety amongst some executives with pharmaceutical companies. The worry is a less strict Food and Drug Administration... 
Cigna Changes to Generic EpiPen, CVS Cuts Prices

Cigna Changes to Generic EpiPen, CVS Cuts Prices

Health insurance behemoth Cigna announced earlier this week it was dropping its coverage for brand name EpiPens that cost $600, while drugstore chain CVS has close to halved the price of epinephrine auto injector Adrenaclick to just... 
Pfizer and OPKO Drug for Growth Hormone Deficiency Fails Study

Pfizer and OPKO Drug for Growth Hormone Deficiency Fails Study

OPKO Health announced that its experimental drug designed to help fight GHD or growth hormone deficiency in adults has failed to produce statistically significant benefits versus a placebo in a study that was “late-stage.” The... 
Ebola Vaccine Shown to Work in New Study

Ebola Vaccine Shown to Work in New Study

An experimental vaccine against Ebola completely protected recipients from the deadly virus near the end of the recent epidemic in West Africa reported researchers. The same strategy was used that was also used for the eradication... 
Mylan Releasing Generic, Half Price EpiPen

Mylan Releasing Generic, Half Price EpiPen

Mylan will release a new generic version of its EpiPen the emergency treatment for allergies at half the price that the original branded version costs. The price of the original has drawn much scorn from parents across the country... 
Two Charged By Feds in Probe Over Price Fixing

Two Charged By Feds in Probe Over Price Fixing

Two former executives with a company that make generic drugs were charged this week for alleged roles they played in a bid-rigging and price-fixing scheme that involved a diabetes medication and an antibiotic. Former CEO of Heritage... 
Eli Lilly Alzheimer’s Drug Does Not Pass the Test

Eli Lilly Alzheimer’s Drug Does Not Pass the Test

A large clinical trial for a drug that treats dementia that is caused by Alzheimer’s ended for Eli Lilly in failure after the people receiving the drug did not show significant improvements compared to those who took a placebo. The... 
CVS Says Prescriptions Shifting, Shares Plummet on Warning

CVS Says Prescriptions Shifting, Shares Plummet on Warning

The largest drugstore chain in the U.S. warned it could lose over 40 million prescriptions in 2017 as deals have been signed by Walgreens Boot Alliance with other participants that have shut CVS pharmacies out of the drug supply chain. CVS,... 
Pfizer Misses Forecasts Net Income Plummets

Pfizer Misses Forecasts Net Income Plummets

U.S. based pharmaceutical giant Pfizer saw its profit for the third quarter plummet over 38% as bigger spending and large charges related to its acquisitions were able to more than offset its higher sales. The U.S. drug maker’s mediocre... 
Merck Posts Rise in Both Revenue and Profit

Merck Posts Rise in Both Revenue and Profit

Merck & Co posted an increase in both its revenue as well as profit as its closely watched treatment for cancer and its vaccines boosted its results. Shares were up 2.5% during trading before the bell as the company’s results... 
Roche Sees Sales Increase Thanks to Cancer Treatments

Roche Sees Sales Increase Thanks to Cancer Treatments

Roche Holding AG announced that sales increased during its third quarter due to strong growth in several of its immunotherapy and cancer drugs. The healthcare behemoth based in Basel, Switzerland announced revenue had grown by 4.5%... 
Johnson & Johnson Helped Again by Its Pharmaceuticals

Johnson & Johnson Helped Again by Its Pharmaceuticals

The pharmaceutical business of Johnson & Johnson was able to help the company lift its low end of guidance and post results that were better than had been anticipated for the most recent quarter, as it continues to help the company’s... 
Johnson & Johnson Drug Tops Humira in Psoriasis Study

Johnson & Johnson Drug Tops Humira in Psoriasis Study

The experimental drug from Johnson & Johnson for psoriasis met its major goals as well as beat a rival in a final stage study related to psoriasis. That has positioned J&J to grow its line-up of immune-disease medications. The... 
FDA Approves New Insulin Pump

FDA Approves New Insulin Pump

The U.S. Food and Drug Administration has approved the sale of a device that is a substantial advance toward an artificial pancreas for patients with Type 1 diabetes. This insulin pump, which has been long awaited, has the goal of... 
New CEO at GlaxoSmithKline Joins Small Group of Women

New CEO at GlaxoSmithKline Joins Small Group of Women

The recent appointment by GlaxoSmithKline of Emma Walmsley as CEO put her on a short list to become the highest profile female in corporate Britain. Walmsley, who is 47, will take the post of CEO in 2017 when Andrew Witty the current... 
Johnson & Johnson Acquires Eye Surgery Unit from Abbott

Johnson & Johnson Acquires Eye Surgery Unit from Abbott

Johnson & Johnson have agreed to purchase the eye-surgery equipment business of Abbott Laboratories for the price of $4.33 billion, which moves the giant in healthcare towards its set goal of increasing all three of its core businesses. This... 
Senators Urge EpiPen Scrutiny Over Increase in Price

Senators Urge EpiPen Scrutiny Over Increase in Price

Two United States Senators have raised concerns about huge increases of price on a drug that is used for emergency conditions when there is a food allergy reaction. Senator Chuck Grassley of Iowa wrote to Mylan the maker of the drug... 
Valeant Pharmaceuticals Posts Earnings That Miss

Valeant Pharmaceuticals Posts Earnings That Miss

Valeant Pharmaceuticals posted revenue and earnings for the quarter that came up short of expectations on Wall Street on Tuesday, but kept its forecast for the full year as it attempts to restore confidence in its investors after its... 
Bristol Myers Says Opdivo Did Not Meet Endpoint in Study

Bristol Myers Says Opdivo Did Not Meet Endpoint in Study

The surprise failure of a cancer drug in a clinical trial slashed over $20 billion off the market value of Bristol-Myers Squibb on Friday, and increased the questions about one of the hottest research areas of the industry; drugs that... 
Pfizer’s New Products Help Profit for First Quarter

Pfizer’s New Products Help Profit for First Quarter

Newer drugs such as Ibrance for breast cancer and Lyrica for nerve pain sold well during the quarter helping U.S. based Pfizer. The pharmaceutical giant reported results that were better than had been expected for the second quarter... 
AbbVie Increases Forecast on Profit Due to Strong Sales of Humira

AbbVie Increases Forecast on Profit Due to Strong Sales of Humira

AbbVie posted quarterly revenue and profit that was higher than had been expected driven by the demand for Humira its flagship drug, and increased its forecast for earnings for the full year. Humira, the biggest selling drug in the... 
Roche Tops Forecasts for the Quarter

Roche Tops Forecasts for the Quarter

Roche based in Switzerland, beat expectations of the market for its net income during the first half of the year with help from sales of a cancer drug along with a big one-off gain in its pension plan. Core earnings a share, adjusted... 
Novartis Releases Profit Warning

Novartis Releases Profit Warning

Swiss pharmaceutical giant Novartis AG lowered its guidance for profit for the full year as it increases its investment in its new drug for heart failure to offset dropping sales of Gleevec its blockbuster cancer drug. Joe Jimenez... 
Rite Aid Posts Sales and Profit That Miss

Rite Aid Posts Sales and Profit That Miss

Drugstore chain Rite Aid said reductions in drug costs would be short of their expectations in the short term. Rite Aid Corp, posted sales and earnings that disappointed for its just ended first quarter amidst pressure from pharmacy... 
Valeant Pharmaceuticals Sales Plunge for Key Drugs, Cuts Forecast

Valeant Pharmaceuticals Sales Plunge for Key Drugs, Cuts Forecast

Canada based Valeant Pharmaceuticals International has a problem with its underlying business not its critics or leadership. Shares of the pharmaceutical company plunged during early Tuesday trading as its new CEO Joseph Papa cut the... 
Jazz Pharmaceuticals to Acquire Celator for $1.5 Billion

Jazz Pharmaceuticals to Acquire Celator for $1.5 Billion

Jazz Pharmaceuticals has agreed to purchase Celator Pharmaceuticals in a deal that is worth approximately $1.5 billion, which represents a large premium for a business that has a promising drug for leukemia but still no revenue. Jazz... 
CVS Health Increase Access to Overdose Treatment

CVS Health Increase Access to Overdose Treatment

On Wednesday, CVS Health Corp the chain of drugstores said it would be expanding the access to the drug naloxone, which is an opioid overdose reversal treatment, to seven more states during the summer. The program of the company to... 
Scientists Find Warfarin Use Associated with Higher Dementia Risk

Scientists Find Warfarin Use Associated with Higher Dementia Risk

The most recent data indicates that atrial fibrillation (A-Fib or AF) is the most common form of heart arrhythmia. A heart arrhythmia is the term given to an anomaly in which the heart beats to slowly or too fast or in an otherwise... 
Merck Sees Drop in Revenue on Competition From Generics

Merck Sees Drop in Revenue on Competition From Generics

Merck & Co announced a drop in revenue as competition from generic drugs and fluctuations in currency hurt the company’s results. Nasonex an allergy drug had 21% less sales, as a generic version was available during the quarter... 
St. Jude Medical to be Acquired by Abbott Laboratories for $25 Billion

St. Jude Medical to be Acquired by Abbott Laboratories for $25 Billion

Abbott Laboratories the healthcare giant has entered into a deal to purchase St. Jude Medical the maker of medical devices in a cash and stock transaction that has been estimated at $25 billion. On Thursday, the two companies revealed... 
FDA Forces Panel to Vote on Muscle Drug Sarepta

FDA Forces Panel to Vote on Muscle Drug Sarepta

Sarepta Therapeutics’ drug to treat a muscle wasting disease was given a new lifeline on Friday after the U.S. Food and Drug Administration forced a panel of independent experts to make a definite recommendation on if the drug should... 
Novartis Overcomes Heart Drug and Eye Care Problem with Older Drugs

Novartis Overcomes Heart Drug and Eye Care Problem with Older Drugs

On Thursday, Novartis was able to beat forecasts for profit thanks to strong performances from older medicines, making up for its eye care business that continues to struggle and the extra costs due to a poor start for its new drug... 
New Inversion Rules in U.S. Could Threaten Deal with Pfizer and Allergan

New Inversion Rules in U.S. Could Threaten Deal with Pfizer and Allergan

The Treasury Department in the U.S. took additional steps Monday to curb the corporate inversion set up to avoid taxes, with a possibly casualty being the pending merger between Allergan and Pfizer. These changes, which are less than... 
Decline in Number of Settlements with Big Pharmaceuticals in U.S.

Decline in Number of Settlements with Big Pharmaceuticals in U.S.

The amount of big money from U.S. pharmaceuticals coming from settlements for violating healthcare laws has dropped sharply in the past few years. This has prompted a watchdog, non-profit group to call for enforcement efforts to increase. In... 
Study Finds Results that are Irregular in Theranos Medical Tests

Study Finds Results that are Irregular in Theranos Medical Tests

Blood tests using the finger performed by Theranos, the startup in the medical industry, produced more results that were irregular than the conventional tests that are offered by the two biggest clinical labs in the nation, said researchers... 
UK’s NICE Changes Mind, Recommends Prostate Drug Zytiga

UK’s NICE Changes Mind, Recommends Prostate Drug Zytiga

The National Institute for Health and Care Excellence or NICE issued its final guidance that recommended Zytiga made by Janssen for the treatment of advanced prostate cancer prior to chemotherapy. The decision by NICE, follows the... 
Cannabis Drug Treats Epilepsy Successfully

Cannabis Drug Treats Epilepsy Successfully

An experimental drug that is cannabis based has treated successfully children that have a rare type of severe epilepsy in a clinical trial that was highly anticipated. The news helped to double the value of GW Pharmaceuticals the maker... 
GlaxoSmithKline Ends One Relationship with Five Prime

GlaxoSmithKline Ends One Relationship with Five Prime

GlaxoSmithKline the pharmaceutical giant based in the UK has cut its ties with Five Prime Therapeutics in cancer therapy development backing out during an ongoing mesothelioma trial. GSK handed a 180-day notice to Five Prime that it... 
Victoza Lowers Number of Cardiovascular Adverse Events

Victoza Lowers Number of Cardiovascular Adverse Events

Novo Nordisk announced on Friday that people who have type 2 diabetes and take Victoza are less prone to have a major cardiovascular adverse event, according to a large study that looked at data from over 9,000 people over a period... 
Sun Pharma Ending Venture With Merck

Sun Pharma Ending Venture With Merck

Sun Pharmaceuticals the drug maker based in India and Merck, Sharp & Dohme’s or MSD have decided mutually to wind down a joint venture because of changes in the strategic priorities of both parents companies. The just taken decision... 
Sanofi: Earnings in 2016 Will Be Stable

Sanofi: Earnings in 2016 Will Be Stable

Sanofi announced that it expects its per share earnings to be stable during 2016 after it reported lower income during the fourth quarter on Tuesday. Income was hurt by a drop in sales of its cancer and diabetes treatments, as well... 
Pfizer Beats Estimates for Earnings on Sales Growth

Pfizer Beats Estimates for Earnings on Sales Growth

Pfizer Inc has reported earnings for the fourth quarter that beat estimates made by analysts  helped by Ibrance the new cancer treatment as well as the Prevnar vaccine. Earnings reached 53 cents per share, said the company in a prepared... 
Roche Profit Disappoints, Outlook is Muted

Roche Profit Disappoints, Outlook is Muted

Swiss pharmaceutical giant Roche posted net profit for the full year of 2015 that came up short of Wall Street expectations. The forecast of the company of an improvement in 2016 met a skeptical response by the market. Roche is relying... 
Walgreens Beats the Street on Earnings

Walgreens Beats the Street on Earnings

Walgreens Boots Alliance Inc has beaten earnings estimates of analysts for its earnings during its fiscal first quarter, as a strong trend in prescription drug made up for a slump in retail that continues plaguing the business. Walgreens...